Shield Therapeutics 'in a strong position' and confident of a US Feraccru deal

Shield Therapeutics (LON:STX) chief financial officer Tim Watts talks Proactive London's Andrew Scott through their first half update to June 2019.

''If you consider where we've been over the last 12 months we're in a far, far stronger position now and with the US approval of Feraccru we're in a good place''.

''We have to convert that into a deal but we believe we have every prospect of doing that''.

''The approval in the US is great ...it should be extremely attractive to a significant number of partners and gives us a great deal of confidence that we can get a deal done''.

shield therapeutics,tim watts,